Angiotensin-converting enzyme inhibitors in adults with cyanotic congenital heart disease

American Journal of Cardiology

Volumn 77, Issue 5, 1996, Pages 439-440

  Hopkins, William E ^a   Kelly, Daniel P ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CYANOTIC HEART DISEASE; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEART HEMODYNAMICS; HUMAN; MALE; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0030028035     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89382-4     Document Type: Article

References (5)

1. Gavras H. Angiotensin-converting enzyme inhibition and the heart. Hypertension 1994;23:813-818.
2. The Criteria Committee, New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Blood Vessels. 6th ed. Boston: Little, Brown, 1964:114.
3. Herman W, Wood SC, Yabek SM, Dillon T, Fripp RR, Burstein R. Systemic oxygen transport in patients with congenital heart disease. Circulation 1987:75: 360-368.
4. Rudolph AM. Congenital Diseases of the Heart. Chicago: Year Book Medical Publishers, 1974:124-126.
5. Barnea O, Austin EH, Richman B, Santamore WP. Balancing the circulation: theoretic optimization of pulmonary/systemic flow ratio in hypoplastic left heart syndrome. J Am Coll Cardiol 1994;24:1376-1381.